GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Total Payout Ratio

MindBio Therapeutics (XCNQ:MBIO) Total Payout Ratio : 0.00 (As of May. 27, 2024)


View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

MindBio Therapeutics's current Total Payout Ratio is 0.00.


MindBio Therapeutics Total Payout Ratio Historical Data

The historical data trend for MindBio Therapeutics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Total Payout Ratio Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Total Payout Ratio
- -0.11 0.27

MindBio Therapeutics Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MindBio Therapeutics's Total Payout Ratio

For the Biotechnology subindustry, MindBio Therapeutics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MindBio Therapeutics's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's Total Payout Ratio falls into.



MindBio Therapeutics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

MindBio Therapeutics's Total Payout Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 1.024 + 0) / -3.823
=0.27

MindBio Therapeutics's Total Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / 0.059
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MindBio Therapeutics Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MindBio Therapeutics (XCNQ:MBIO) Business Description

Traded in Other Exchanges
Address
91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.

MindBio Therapeutics (XCNQ:MBIO) Headlines